Evolus (EOLS) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evolus (EOLS) has outperformed Neurogene (NGNE) over the past year, gaining 25.6% versus a gain of 2.6%. Over five years, EOLS leads with a +1.7% price change compared with -81.6% for NGNE. Neurogene is the larger company by market cap ($530.3 million vs $515.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | NGNE |
|---|---|---|
| Share price | $7.80 | $26.50 |
| Market cap | $515.19M | $530.30M |
| 1-day change | +0.78% | +2.44% |
| YTD return | +17.29% | +28.64% |
| 1-year return | +25.60% | +2.59% |
| 5-year return | +1.69% | -81.65% |
| Forward P/E | 26.67 | — |
| EPS (TTM) | $-0.53 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $43.66 |
| 52-week low | $3.86 | $15.93 |
| Distance from 52-week high | -16.22% | -39.30% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.31% | +193.89% |
| Average volume | 900.79K | 247.13K |
| Shares outstanding | 66.05M | 20.01M |
| Employees | 353 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed NGNE by 23.0 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
EOLS vs NGNE FAQ
Which is bigger, Evolus or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $530.30M compared with $515.19M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or NGNE?
EOLS returned +25.60% over the past 12 months, compared with +2.59% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.